Last update 31 Jan 2026

Naperiglipron

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
LY 3549492, LY-3549492
Target
GLP-1R
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
ObesityDiabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
Eli Lilly & Co.Eli Lilly & Co.
Active Organization
Eli Lilly & Co.Eli Lilly & Co.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

9
Clinical Trials associated with Naperiglipron
NCT07232732
/ RecruitingPhase 1
A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
NCT07073170
/ RecruitingPhase 1
A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
NCT07085468
/ TerminatedPhase 2
A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2
100 Clinical Results associated with Naperiglipron
Login to view more data
100 Translational Medicine associated with Naperiglipron
Login to view more data
100 Patents (Medical) associated with Naperiglipron
Login to view more data
100 Deals associated with Naperiglipron
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
United States
Eli Lilly & Co.Eli Lilly & Co.
19 Jun 2025
Diabetes Mellitus, Type 2Phase 2
Argentina
Eli Lilly & Co.Eli Lilly & Co.
19 Jun 2025
ObesityPhase 2
United States
Eli Lilly & Co.Eli Lilly & Co.
13 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free